The Combination Effect of Sodium Butyrate, 5-aza-2′-deoxycytidine on the Tumor Suppressive Activity in RKO Colorectal Cancer and MCF-7 Breast Cancer Cell Lines

被引:0
作者
Cho, Hang Joo [1 ]
Park, Sun Cheol [1 ]
Kim, Kee Whan [1 ]
Kang, Won Kyung [1 ]
Cho, Hyun Min [1 ]
Kim, Jeong Soo [1 ]
Kim, Young Ae [1 ]
An, Chang Hyeok [1 ]
机构
[1] Catholic Univ Korea, Coll Med, Dept Surg, Uijongbu, South Korea
来源
JOURNAL OF THE KOREAN SURGICAL SOCIETY | 2009年 / 76卷 / 05期
关键词
Epigenetics; Histone deacetylase inhibitor; Demethylating agent; HISTONE-DEACETYLASE INHIBITORS; DEMETHYLATION; APOPTOSIS; P53/P21(WAF1/CIP1); PROLIFERATION; TRANSCRIPTION; REEXPRESSION; PATHWAY; GENE;
D O I
10.4174/jkss.2009.76.5.279
中图分类号
R61 [外科手术学];
学科分类号
摘要
Purpose: It is known that DNA methylation is associated with historic acetylation status in regulation of gene expression. In this study, we investigate the effect of demethylating agents and histone deacetylase (HDAC) inhibitor on the tumor suppression and the combined effect of two agents according to methylation status in human colon and breast cancer cell lines. Methods: In this Study, the RKO colorectal cancer cell line, MCF-7 breast cancer cell lines were considered. For each cell line, we used HDAC inhibitor sodium butyrate (SB), demethylating agent 5-aza-2'-deoxycytidine (5-aza-DC) and a combination of both agents. We estimated the percentage of cell survival using the XTT method and experimented with the augmentative effects of both agents. Results: In RKO cell line in which most of the genes are methylated, 74% of cell survival was shown for 5-aza-DC treatment and 83% of cell survival for SB treatment. In MCF-7 cell line that approximately half of the genes are methylated, 82% cell Survival was shown for 5-aza-DC treatment and 63% cell survival for SB treatment. We observed that the survival fraction is lower after the combined treatment of 5-aza-DC and SB than that of 5-aza-DC or SB alone in both RKO (53%) and MCF-7 (49%) cell lines (P<0.001). Conclusion: For highly methylated genes, 5-aza-DC is more effective on the tumor suppression than SB. On the other hand, if the methylation of the promoter region is at low density, SB is noted to be more effective than 5-aza-DC. Furthermore, the combined treatment of 5-aza-DC and SB is more effective than using each agent alone. (J Korean Surg Soc 2009;76:279-284)
引用
收藏
页码:279 / 284
页数:6
相关论文
共 21 条
[1]   Histone deacetylase inhibitor and demethylating agent chromatin compaction and the radiation response by cancer cells [J].
Bar-Sela, Gil ;
Jacobs, Kristi Muldoon ;
Gius, David .
CANCER JOURNAL, 2007, 13 (01) :65-69
[2]   Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer [J].
Cameron, EE ;
Bachman, KE ;
Myöhänen, S ;
Herman, JG ;
Baylin, SB .
NATURE GENETICS, 1999, 21 (01) :103-107
[3]   HDAC Inhibitors Act with 5-aza-2′-Deoxycytidine to Inhibit Cell Proliferation by Suppressing Removal of Incorporated Abases in Lung Cancer Cells [J].
Chai, Guolin ;
Li, Lian ;
Zhou, Wen ;
Wu, Lipeng ;
Zhao, Ying ;
Wang, Donglai ;
Lu, Shaoli ;
Yu, Yu ;
Wang, Haiying ;
McNutt, Michael A. ;
Hu, Ye-Guang ;
Chen, Yingqi ;
Yang, Yang ;
Wu, Xin ;
Otterson, Gregory A. ;
Zhu, Wei-Guo .
PLOS ONE, 2008, 3 (06)
[4]   Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription [J].
Fuks, F ;
Burgers, WA ;
Godin, N ;
Kasai, M ;
Kouzarides, T .
EMBO JOURNAL, 2001, 20 (10) :2536-2544
[5]   DNA hypermethylation: when tumour suppressor genes go silent [J].
Garinis, GA ;
Patrinos, GP ;
Spanakis, NE ;
Menounos, PG .
HUMAN GENETICS, 2002, 111 (02) :115-127
[6]   Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer [J].
Johnstone, RW .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) :287-299
[7]   The fundamental role of epigenetic events in cancer [J].
Jones, PA ;
Baylin, SB .
NATURE REVIEWS GENETICS, 2002, 3 (06) :415-428
[8]   Epigenetic changes in colorectal cancer [J].
Kondo, Y ;
Issa, JPJ .
CANCER AND METASTASIS REVIEWS, 2004, 23 (1-2) :29-39
[9]   Histone deacetylases and cancer: Causes and therapies [J].
Marks, PA ;
Rifkind, RA ;
Richon, VM ;
Breslow, R ;
Miller, T ;
Kelly, WK .
NATURE REVIEWS CANCER, 2001, 1 (03) :194-202
[10]   Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells [J].
Marks, PA ;
Richon, VM ;
Rifkind, RA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (15) :1210-1216